Kinastad comp 10 mg/12,5 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kinastad comp 10 mg/12,5 mg filmdragerad tablett

stada arzneimittel ag - hydroklortiazid; kinaprilhydroklorid - filmdragerad tablett - 10 mg/12,5 mg - kinaprilhydroklorid 10,83 mg aktiv substans; hydroklortiazid 12,5 mg aktiv substans - kinapril och diuretika

Kinastad comp 20 mg/12,5 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kinastad comp 20 mg/12,5 mg filmdragerad tablett

stada arzneimittel ag - hydroklortiazid; kinaprilhydroklorid - filmdragerad tablett - 20 mg/12,5 mg - kinaprilhydroklorid 21,66 mg aktiv substans; hydroklortiazid 12,5 mg aktiv substans - kinapril och diuretika

Kinastad comp 20 mg/25 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kinastad comp 20 mg/25 mg filmdragerad tablett

stada arzneimittel ag - hydroklortiazid; kinaprilhydroklorid - filmdragerad tablett - 20 mg/25 mg - hydroklortiazid 25 mg aktiv substans; kinaprilhydroklorid 21,66 mg aktiv substans - kinapril och diuretika

Kinastad 10 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kinastad 10 mg filmdragerad tablett

stada arzneimittel ag - kinaprilhydroklorid - filmdragerad tablett - 10 mg - kinaprilhydroklorid 10,83 mg aktiv substans - kinapril

Kinastad 20 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kinastad 20 mg filmdragerad tablett

stada arzneimittel ag - kinaprilhydroklorid - filmdragerad tablett - 20 mg - kinaprilhydroklorid 21,66 mg aktiv substans - kinapril

Kinastad 40 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kinastad 40 mg filmdragerad tablett

stada arzneimittel ag - kinaprilhydroklorid - filmdragerad tablett - 40 mg - kinaprilhydroklorid 43,32 mg aktiv substans - kinapril

Kinastad 5 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kinastad 5 mg filmdragerad tablett

stada arzneimittel ag - kinaprilhydroklorid - filmdragerad tablett - 5 mg - kinaprilhydroklorid 5,42 mg aktiv substans - kinapril

Tecartus Europeiska unionen - svenska - EMA (European Medicines Agency)

tecartus

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcell - antineoplastiska medel - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Xalkori Europeiska unionen - svenska - EMA (European Medicines Agency)

xalkori

pfizer europe ma eeig - crizotinib - carcinom, non-small cell lung - antineoplastiska medel - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Alunbrig Europeiska unionen - svenska - EMA (European Medicines Agency)

alunbrig

takeda pharma a/s - brigatinib - carcinom, non-small cell lung - antineoplastiska medel - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.